American Heart Journal
Volume 155, Issue 1 , Pages 56-61, January 2008

Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression

Sinai Center for Thrombosis Research, Baltimore, MD

Received 10 May 2007; accepted 22 August 2007. published online 08 October 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The study was supported by Bayer HealthCare LLC, Morristown, NJ, and Sinai Hospital of Baltimore.

 Dr Paul A. Gurbel has received honoraria and grants from Haemoscope, Niles, IL; Astra Zeneca, London, United Kingdom; Schering Plough, Kenilworth, NJ; Medtronic, Minneapolis, MN; Lilly/Sankyo Sanofi, Paris, France; Boston-Scientific, Natick, MA; and Bayer, Pittsburgh, PA.

PII: S0002-8703(07)00707-7

doi:10.1016/j.ahj.2007.08.021

American Heart Journal
Volume 155, Issue 1 , Pages 56-61, January 2008

Article Tools